New Scoring Method Pinpoints the Rare Genetic Variants That Matter Most for Common Diseases

One of the most stubborn puzzles in human genetics has just been handed a powerful new tool. A research team led by Guillaume Paré at McMaster University’s Population Health Research Institute has developed a computational method called RovHer, which stands for rare variant heritability-optimized scores, that can identify which of the millions of rare mutations scattered through our protein-coding genes actually influence disease risk. Published in Nature Genetics, the study demonstrates that a tiny fraction of rare missense variants, those single-letter DNA changes that swap one amino acid for another in a protein, accounts for a strikingly large share of the inherited variation in complex traits such as height, cholesterol levels and kidney function. The finding has immediate implications for how genetic risk scores are built and how carriers of potentially dangerous mutations are identified in clinical settings.

The motivation behind the work lies in what geneticists call the missing heritability problem. Genome-wide association studies have catalogued thousands of common genetic variants linked to common diseases, yet together these variants explain only a portion of the heritability estimated from family studies. Rare variants, defined here as those carried by fewer than one percent of the population, have long been suspected of hiding much of the missing signal. Population-scale sequencing efforts, including the exome sequencing of nearly half a million UK Biobank participants, have uncovered millions of these rare missense variants. The difficulty is that the overwhelming majority of them are evolutionarily young, present in only one or a few individuals, and statistically almost impossible to test for association one at a time. Distinguishing the functional few from the neutral many has remained one of the field’s central challenges.

RovHer attacks the problem from an unusual angle. Instead of asking whether a variant is deleterious to a protein in the abstract, the method asks whether a variant contributes to the variance of a measurable trait in a real population. The researchers trained their model using exome-wide association statistics covering 4,927,334 rare variants, treating the statistical evidence of association as a noisy label of functionality. On top of that foundation, they used a machine-learning technique known as multivariate adaptive regression splines, or MARS, to integrate 75 different features describing each variant and the gene it sits in. These features ranged from conservation measures and protein-domain information to gene-level annotations such as tolerance to loss-of-function mutations. Crucially, the MARS framework imposes no a priori constraints on how these features should be combined, allowing the data to reveal nonlinear interactions, for example cases where a variant’s importance depends on the properties of the gene it inhabits.

The benchmark results are dramatic. Across 21 quantitative traits measured in up to 357,086 individuals of European ancestry in the UK Biobank, the top one percent of variants prioritized by RovHer, a set of just 13,410 missense variants, explained on average 16.1 percent of the total heritability attributable to rare missense variation. Seven widely used alternative methods, including established pathogenicity predictors such as CADD, REVEL and AlphaMissense, managed an average of only 1.5 percent, with the best performer reaching 2.3 percent. In other words, RovHer achieved roughly a tenfold gain over the existing state of the art. Because the evaluation metric was heritability explained rather than agreement with laboratory assays or clinical classifications, the comparison directly measured what matters most for complex-trait genetics: how much inherited variation a prioritized variant set actually captures.

The authors were careful to rule out trivial explanations for this performance. RovHer’s predictions proved independent of allele frequency, meaning the method is not simply rewarding variants that happen to be slightly more common and therefore easier to detect statistically. The scores also generalized beyond the population in which they were trained. In a replication analysis using whole-genome sequencing data from the National Institutes of Health’s All of Us Research Program, RovHer outperformed competing methods across European, African and Admixed American ancestry groups, with sample sizes of 172,108, 61,620 and 52,645 respectively. This multi-ancestry validation matters because rare variant landscapes differ substantially between populations, and tools trained exclusively on European data have historically underperformed elsewhere.

Beyond population-level statistics, the team tested whether RovHer could identify individual carriers at elevated risk of severe clinical outcomes. Across 17 monogenic gene-trait pairs, where a single gene is known to exert a strong effect on a specific condition, high-scoring variants effectively flagged carriers with increased disease risk. Examples included variants in LDLR, the low-density lipoprotein receptor gene whose pathogenic mutations cause familial hypercholesterolemia, and variants in SLC34A3, a sodium-dependent phosphate transporter gene linked to kidney stone disease and altered estimated glomerular filtration rates. The analysis showed that carriers of top-ranked missense variants in these genes had measurably worse kidney function and higher chronic kidney disease risk than non-carriers, suggesting the method can bridge the gap between statistical genetics and clinical risk stratification.

Technically, the choice of MARS proved central to the method’s success. Unlike deep neural networks, which can be difficult to interpret, multivariate adaptive regression splines fit piecewise linear functions with hinge points, producing a model whose behavior can be inspected through partial dependence plots and variable importance measures. This allowed the researchers to see which of the 75 input features drove predictions and where thresholds lay. The team also demonstrated robustness to training choices: models trained on height, body mass index, creatinine or apolipoprotein B each performed well when tested on other traits, and adding more training traits provided incremental gains rather than overfitting. This suggests the method captures general principles of variant functionality rather than quirks of any single phenotype.

Perhaps the most practical aspect of the study is its accessibility. The researchers have released RovHer scores for all 4,927,334 rare variants observed in the UK Biobank, along with precomputed scores for approximately 80 million potential single-nucleotide rare variants across the human exome, hosted on Zenodo. The software package runs offline on all major operating systems, requires only a simple tab-delimited file of variant identifiers as input, and is free for noncommercial use, with a version stripped of commercially licensed prediction methods also provided. Tutorials and accompanying code for rare variant heritability estimation are available on GitHub. For biobank-scale analyses the authors recommend Unix-based hardware with at least 300 gigabytes of memory, but individual variant scoring is far lighter.

The broader significance of the work lies in its reframing of rare variation’s role in common disease. Rather than treating rare missense variants as an undifferentiated mass too sparse to analyze, RovHer shows that a small, computationally identifiable subset carries a disproportionate share of trait-relevant signal. This opens the door to incorporating rare variant information into polygenic risk scores, which currently rely almost entirely on common variants, and to prioritizing which variants of uncertain significance in clinical exomes deserve the closest scrutiny. It also complements recent work showing that rare penetrant mutations confer severe risks for common diseases, and that the genetic architecture of complex traits differs in the tails of their distributions.

Limitations remain, as with any predictive model. RovHer was trained on European-ancestry UK Biobank data, and while its multi-ancestry replication is encouraging, further calibration across diverse populations will be needed as adoption spreads. The method also inherits the limitations of its input features, since variants in poorly characterized genes or genomic regions with sparse annotations may be scored less reliably. Nonetheless, the tenfold improvement in heritability capture, the clinical validation across monogenic gene-trait pairs and the open availability of scores for essentially every possible exomic variant make RovHer a landmark addition to the geneticist’s toolkit. As sequencing continues to expand across global populations, heritability-optimized approaches of this kind are likely to become standard instruments for separating the functional signal from the neutral noise in the rare variant universe.

Subject of Research: Heritability-optimized functional prioritization of rare coding variants in complex traits

Article Title: A heritability-optimized method for functional prioritization of rare coding variants in complex traits

Article References: Pang, K., Pathan, N., Le, A., Man, A., Graf, J., Li, Y., da Rocha, G. L., Shemesh, E., Grafodatskaya, D., Chong, M. R., & Paré, G. (2026). A heritability-optimized method for functional prioritization of rare coding variants in complex traits. Nature Genetics. https://doi.org/10.1038/s41588-026-02766-w

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02766-w

Keywords: rare variants, missense variants, heritability, complex traits, UK Biobank, RovHer, variant effect prediction, machine learning, genetic risk, population genetics, monogenic disease, exome sequencing